NASDAQ:ITRM Iterum Therapeutics (ITRM) Stock Price, News & Analysis $0.03 0.00 (0.00%) As of 05/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Iterum Therapeutics Stock (NASDAQ:ITRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Iterum Therapeutics alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.1852-Week Range$0.03▼$1.42VolumeN/AAverage Volume4.85 million shsMarket Capitalization$1.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance. The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI). Iterum’s development strategy seeks to leverage the broad spectrum of activity exhibited by sulopenem against resistant Gram-negative pathogens, with the goal of offering a seamless transition from hospital to outpatient care via its oral formulation. Incorporated in 2014 and headquartered in Dublin, Ireland, Iterum Therapeutics maintains additional operations in the United States, including a presence in Malvern, Pennsylvania, to support clinical and regulatory activities. The company is backed by a management team and board with extensive experience in anti-infective drug discovery, clinical development and life-cycle management. Iterum continues to advance its pipeline through ongoing regulatory interactions and clinical studies aimed at meeting unmet medical needs in infectious diseases.AI Generated. May Contain Errors. Read More Iterum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreITRM MarketRank™: Iterum Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingReduce Consensus RatingIterum Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageIterum Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Iterum Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Iterum Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iterum Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ITRM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIterum Therapeutics does not currently pay a dividend.Dividend GrowthIterum Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for ITRM on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat Follows2 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Iterum Therapeutics is held by insiders.Percentage Held by Institutions9.21% of the stock of Iterum Therapeutics is held by institutions.Read more about Iterum Therapeutics' insider trading history. Receive ITRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ITRM Stock News HeadlinesHC Wainwright & Co. downgrades Iterum Therapeutics (ITRM)March 31, 2026 | msn.comWhat's going on with Iterum Therapeutics stock Monday?March 30, 2026 | msn.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 27 at 1:00 AM | Brownstone Research (Ad)Iterum files wind-up petition due to limited cash, inability to raise equityMarch 27, 2026 | reuters.comIterum Therapeutics Announces Filing of Winding Up PetitionMarch 27, 2026 | globenewswire.comIterum Therapeutics (ITRM) price target increased by 63.64% to 9.18March 27, 2026 | msn.comIterum Therapeutics Provides Business UpdateFebruary 13, 2026 | globenewswire.comIterum Therapeutics PLCJanuary 17, 2026 | barrons.comSee More Headlines ITRM Stock Analysis - Frequently Asked Questions How have ITRM shares performed this year? Iterum Therapeutics' stock was trading at $0.3350 at the beginning of 2026. Since then, ITRM stock has decreased by 91.0% and is now trading at $0.03. How were Iterum Therapeutics' earnings last quarter? Iterum Therapeutics PLC (NASDAQ:ITRM) released its earnings results on Friday, November, 14th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.07. The company earned $0.39 million during the quarter. Read the conference call transcript. When did Iterum Therapeutics' stock split? Shares of Iterum Therapeutics reverse split on the morning of Thursday, August 18th 2022.The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Iterum Therapeutics IPO? Iterum Therapeutics (ITRM) raised $92 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 6,150,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. How do I buy shares of Iterum Therapeutics? Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Iterum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include NVIDIA (NVDA), Zoom Communications (ZM), Tesla (TSLA), Meta Platforms (META), SNDL (SNDL) and Atossa Genetics (ATOS). Company Calendar Last Earnings11/14/2025Today5/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ITRM's financial health is in the Red zone, according to TradeSmith. ITRM has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITRM CIK1659323 Webwww.iterumtx.com Phone(531) 669-4820FaxN/AEmployees10Year Founded2015Profitability EPS (Trailing Twelve Months)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.77 million Net MarginsN/A Pretax Margin-6,842.31% Return on EquityN/A Return on Assets-65.54% Debt Debt-to-Equity RatioN/A Current Ratio2.13 Quick Ratio1.96 Sales & Book Value Annual Sales$390 thousand Price / Sales4.10 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-0.20Miscellaneous Outstanding Shares53,292,000Free Float52,226,000Market Cap$1.60 million OptionableNot Optionable Beta2.96 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ITRM) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
